Photobiology Unit, Ninewells Hospital, Dundee, UK.
Clin Exp Dermatol. 2012 Apr;37(3):219-26. doi: 10.1111/j.1365-2230.2011.04256.x. Epub 2012 Jan 25.
Whole-body ultraviolet (UV)A1 (340-400 nm) phototherapy was first introduced 30 years ago, but is currently available in the UK in only three dermatology departments. A workshop to discuss UVA1 was held by the British Photodermatology Group in May 2009, the aim of which was to provide an overview of UVA1 phototherapy and its role in practice, and to identify areas in which further studies are required. The conclusions were that UVA1 phototherapy is an effective treatment in several inflammatory skin diseases, including localized scleroderma and atopic eczema (AE); however, deficiencies and limitations exist in the published evidence base. For most diseases, such as AE, other treatments also exist, which are generally more effective than UVA1. However, for some diseases, particularly morphoea, the evidence of efficacy is stronger for UVA1 than for other treatments. Acute adverse effects of UVA1 are minimal. The risk of long-term adverse effects, particularly skin cancer, is unknown. Medium to high doses of UVA1 are needed for efficacy in most situations, but the equipment to deliver such doses is large, expensive and difficult to install. UVA1 is currently underprovided, and the recommendation of the workshop is that more tertiary centres should have access to UVA1 phototherapy in the UK.
全身紫外线 A1（340-400nm）光疗在 30 年前首次引入，但目前在英国仅有三个皮肤科部门提供该治疗。2009 年 5 月，英国光皮肤病学组举行了一次关于 UVA1 的研讨会，旨在提供 UVA1 光疗及其在实践中的作用概述，并确定需要进一步研究的领域。结论是 UVA1 光疗在几种炎症性皮肤病中有效，包括局限性硬皮病和特应性皮炎（AE）；然而，在已发表的证据基础中存在缺陷和局限性。对于大多数疾病，如 AE，还有其他更有效的治疗方法。然而，对于某些疾病，特别是硬斑病，UVA1 的疗效证据比其他治疗方法更强。UVA1 的急性不良反应极小。长期不良反应的风险，特别是皮肤癌，尚不清楚。在大多数情况下，中高剂量的 UVA1 是有效的，但提供这种剂量的设备体积大、昂贵且难以安装。目前 UVA1 的供应不足，研讨会的建议是英国应该有更多的三级中心能够获得 UVA1 光疗。
